REATA PHARMACEUTICALS INC-A (RETA)

US75615P1030 - Common Stock

172.36  +0.04 (+0.02%)

After market: 172.4 +0.04 (+0.02%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
9.02M
-65.99%		11.49M
27.38%		2.216M
-80.71%		92.691M
4,082.81%
EBITDA
YoY % growth
-225.19M
20.79%		-243.505M
-8.13%		-276.904M
-13.72%		-312.868M
-12.99%
EBIT
YoY % growth
-226.33M
20.65%		-244.708M
-8.12%		-278.034M
-13.62%		-369.477M
-32.89%
Operating Margin
-2,509.20%-2,129.75%-12,546.66%-398.61%
EPS
YoY % growth
-6.98
-38.77%		-8.18
-17.19%		-8.54
-4.40%		-6.81
20.24%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q3 / 23 Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-2.13
1.24%
Revenue
Q2Q % growth		29.575M
5,376.85%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-81.578M
-15.74%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q2 2023
Q2Q % growth		 4.65
330.20%		-2.937.58258.50%
Q1 2023
Q2Q % growth		 -3.14
-54.68%		-2.47-0.67-27.16%
Q4 2022
Q2Q % growth		 -2.33
0.85%		-2.25-0.08-3.37%
Q3 2022
Q2Q % growth		 -2.16
-9.64%		-2.230.072.92%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q2 2023
Q2Q % growth		 22.746M
2,885.04%		120.87K22.625M18,718.57%
Q1 2023
Q2Q % growth		 195K
-78.67%		161.415K33.585K20.81%
Q4 2022
Q2Q % growth
-100.00%		501.259K-501.259K-100.00%
Q3 2022
Q2Q % growth		 540K
-92.69%		658.155K-118.155K-17.95%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 13.57% 35.98% 25.36%
Revenue0% 51.67% 67.27% 122.64%